The 3 analysts offering 12-month price forecasts for Acer Therapeutics Inc have a median target of 10.00, with a high estimate of 10.00 and a low estimate of 3.52. The median estimate represents a +95.69% increase from the last price of 5.11.
The current consensus among 5 polled investment analysts is to Hold stock in Acer Therapeutics Inc. This rating has held steady since February, when it was downgraded from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.38
Reporting Date Aug 18
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.